DNA X, Inc. (SONM) Earnings History
Net Loss9 years of earnings data (2017–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
DNA X, Inc. (SONM) Earnings Overview
As of June 23, 2026, DNA X, Inc. (SONM) reported trailing twelve-month net income of -$15M, reflecting +77.7% year-over-year growth. The company earned $-1.17 per diluted share over the past four quarters.
Looking at the long-term picture, SONM's historical earnings data spans multiple years. The company achieved its highest annual net income of $1M in fiscal 2018.
DNA X, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including LIQT (-$9M net income, -51.7% margin), KOSS (-$1M net income, -6.9% margin), NTGR (-$40M net income, -4.7% margin), SONM has comparable earnings metrics. Compare SONM vs LIQT →
SONM Earnings vs Peers
Earnings metrics vs comparable public companies
SONM Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$21M | +38.6% | -$5M | $-1.59 | - | - |
| 2024 | -$34M | -37286.7% | -$34M | $-7.13 | -57.7% | -57.7% |
| 2023 | $-90,000 | +99.4% | $513,000 | $-0.02 | -0.1% | 0.5% |
| 2022 | -$14M | +63.5% | -$14M | $-4.88 | -20.2% | -20.5% |
| 2021 | -$39M | -29.0% | -$38M | $-40.81 | -70.8% | -69.6% |
| 2020 | -$30M | -15.9% | -$29M | $-64.78 | -46.8% | -45.7% |
| 2019 | -$26M | -2123.0% | -$22M | $-138.87 | -22.2% | -19.3% |
| 2018 | $1M | +115.0% | $5M | $-257.45 | 0.9% | 4.0% |
| 2017 | -$9M | - | -$7M | $-1495.71 | -14.4% | -11.5% |
Download Data
Export SONM earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SONM — Frequently Asked Questions
Quick answers to the most common questions about buying SONM stock.
What is SONM earnings per share (EPS)?
SONM trailing twelve-month (TTM) diluted EPS is $-1.17, reflecting +77.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2017 to 2025 is available in the table on this page.
What is DNA X, Inc.'s net income?
DNA X, Inc. (SONM) trailing twelve-month net income is $-15M as of 2025. Earnings grew +77.7% year-over-year.
Is SONM profitable?
SONM is not currently profitable on a TTM basis, reporting a net loss of $-15M. Net margin is N/A. Investors should monitor for a return to profitability.
What is SONM's earnings growth rate?
SONM compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2017 to 2025.
What are SONM's profit margins?
DNA X, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is SONM growing earnings?
Yes, SONM earnings are accelerating — EPS growth of +77.7% exceeds the 5-year CAGR of N/A. TTM net income reached $-15M. Earnings momentum is strengthening.
What was SONM's best earnings year?
DNA X, Inc.'s highest annual net income on record is $1M, achieved in fiscal year 2018. Earnings history on this page spans 2017 to 2025 and includes all annual and quarterly figures.
What were SONM's earnings last quarter?
SONM's most recent reported quarter was Q1 2026. Net income was $6M with diluted EPS of $-3.11. For a full breakdown of all quarters, see the quarterly earnings table on this page.